Finally, when prostate cancer cell lines were treated with the CDK4/6 inhibitor PD0332991, the cell lines responded to the treatment according to miR-193b expression/methylation status and cyclin D1 levels. This evidence concerns the gene CDK4 and prostate carcinoma.